8-K current report · filed Oct 14, 2026

Akebia Therapeutics, Inc. (AKBA) 8-K Current Report: October 14, 2026

Item 5.02AKBA overview

Short answer

Akebia Therapeutics, Inc. (AKBA) filed an 8-K current report with the SEC on October 14, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Chief Commercial Officer Nicholas Grund resigns for personal reasons, effective November 6, 2026.

Akebia Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Chief Commercial Officer Nicholas Grund resigns for personal reasons, effective November 6, 2026
  • Consulting arrangement continues through April 30, 2027, supporting commercial transition
  • Hourly consulting compensation and termination notice provisions govern the interim advisory period

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Akebia Therapeutics, Inc. 8-K filings

Get the next AKBA 8-K as it lands

Follow AKBA for push alerts, or ask the research agent what this filing means.